Circulating Tumor Cells in Lung Cancer Screening

NACompletedINTERVENTIONAL
Enrollment

683

Participants

Timeline

Start Date

October 30, 2015

Primary Completion Date

October 13, 2020

Study Completion Date

October 13, 2020

Conditions
Lung NeoplasmsPulmonary Disease, Chronic Obstructive
Interventions
BIOLOGICAL

Isolation of circulating tumor cells (CTC) from veinous blood

Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.

Trial Locations (20)

Unknown

CHU d'Amiens, Amiens

CHU de Dijon, Dijon

CHU de Grenoble, Grenoble

CHRU de Lille, Lille

Hospices Civils de Lyon, Lyon

Hôpital Nord, Marseille

CHU de Montpellier, Montpellier

CHU de Nancy, Nancy

Hôpital Bichat, Paris

Hôpital Cochin, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital TENON, Paris

CHU de Reims, Reims

CHU de Rennes, Rennes

CH de Roubaix, Roubaix

CHU de Rouen, Rouen

CHU de Saint Etienne, Saint-Etienne

CHU de Strasbourg, Strasbourg

CHU de Toulouse, Toulouse

CHU de Tours, Tours

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT02500693 - Circulating Tumor Cells in Lung Cancer Screening | Biotech Hunter | Biotech Hunter